ArticleBMC research notes2026
Clinical outcomes and feasibility of 3D-printed titanium alloy scaffolds combined with platelet-rich plasma injection in the treatment of long-segment femoral defects.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aimed to investigate the clinical efficacy and feasibility of 3D-printed titanium alloy scaffolds combined with autologous platelet-rich plasma (PRP) injection in the treatment of long-segment femoral defects.
resultsThe mean follow-up duration for all patients in this study was 12.63 ± 1.02 months. At the final follow-up, the Visual Analogue Scale (VAS) score was 2.13 ± 1.15, significantly lower than the preoperative score of 6.31 ± 1.74 (P < 0.001). The Lower Extremity Functional Scale (LEFS) score was 54.88 ± 6.01, significantly higher than the preoperative score of 33.81 ± 8.05 (P < 0.001). The Lane–Sandhu score was 7.19 ± 1.38, and the patient-reported satisfaction score was 8.88 ± 1.02. No severe complications were observed during the follow-up period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.